



SITC 2016

NATIONAL HARBOR, MD
NOVEMBER 9-13, 2016



Society for Immunotherapy of Cancer

SITC 2016

NATIONAL HARBOR, MD
NOVEMBER 9-13, 2016

Anti-Semaphorin4D VX15/2503 in Combination with Ipilimumab or Antibody to PD-1 or PD-L1

**Elizabeth Evans, PhD, Vice President, Preclinical Research
Vaccinex, Inc. Rochester NY**



Society for Immunotherapy of Cancer

#SITC2016

Presenter Disclosure Information

Elizabeth Evans

The following relationships exist related to this presentation:

Full-time employee at Vaccinex, Inc.




#SITC2016

Forward Looking Statements

Cautionary Note on Forward-Looking Statements


This presentation contains forward-looking statements reflecting the current beliefs and expectations of Vaccinex management. Words such as “may,” “believe,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions, as well as other words or expressions referencing future events, conditions or circumstances, are intended to identify forward-looking statements. Forward-looking statements contained in this presentation include statements about expectations related to a clinical trial for the Company’s lead monoclonal antibody, VX15/2503. Forward-looking statements in this presentation involve substantial risks and uncertainties that could cause the Company’s performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including as a result of the inherent challenges in clinical development. All forward-looking statements are based on Vaccinex’s expectations and assumptions as of the date of this presentation, and actual results may differ materially. Except as required by law, Vaccinex expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.




SEMA4D inhibits migration of myeloid cells.
Blockade of SEMA4D promotes infiltration of potent APC
and inhibits differentiation/expansion of MDSC, M2 TAM and Treg.
 ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE

SEMA4D expression is concentrated at Invasive Tumor Margin, creating a barrier to immune cell penetration



Mammary carcinoma
Tubo.A5



Colorectal
Colon26




SEMA4D Regulates Migration and Activation of Immune Cells in Tumor Microenvironment in Preclinical Models




Anti-SEMA4D Shifts the Balance of Immune Cells in Tumor Microenvironment

Tumoricidal Cells ↑

Tumor-specific Cytotoxic T Cells




Anti-tumorigenic APC
F4/80+CD11c+




Immuno-suppressive Cells ↓

T_{regulatory} CD4+CD25+




Pro-tumorigenic TAM
CD206+ TAM




MDSC

Gr1+CD11b+ MDSC




Anti-SEMA4D Shifts the balance of Immunity in Tumor Microenvironment

Tumoricidal Factors




Immuno-suppressive Factors



ADVANCING CANCER IMMUNOTHERAPY THROUGHOUT THE WORLD



Anti-SEMA4D enhances Immune Checkpoint blockade




Durable responses, and regressor mice resist subsequent tumor challenge.

Anti-SEMA4D also enhances activity of chemotherapy (cyclophosphamide, etc.) and other immune checkpoint antibodies (anti-PD-1) in preclinical models

ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE

Vaccinex IND, Phase 1b/2 Combination Trial VX15/2503 (humanized IgG4) with Avelumab (anti-PD-L1): NSCLC (2L)




*In collaboration with
Merck KGaA*

Evaluate immune infiltration in tumor biopsies and ORR, DOR

ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE

Investigator sponsored, Phase 1b/2 Combination Trial VX15/2503 (human IgG4) with anti-PD-1 or anti-CTLA-4




Evaluate immune infiltration in tumor biopsies and ORR, DOR

ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE

Anti-SEMA4D Shifts the Immune Balance to Enhance Activity of Immune Checkpoint Inhibitors

Effects of ICP or anti-SEMA4D:

- \uparrow $T_{\text{effectors}}$
- \uparrow Th1 cytokines: IFN γ , TNF α
- \uparrow CXCL9, CXCL10



Combination enhances effects and adds benefits of anti-SEMA4D to facilitate infiltration and reverse suppressive APC:

- \downarrow M2 TAM
- \downarrow MDSC
- \downarrow $T_{\text{regulatory}}$
- \downarrow Chemokines that recruit M2 and polarize Treg: CCL2, CXCL1, CXCL5, IL-10

- **Potential Impact on Field:** The unique mechanism of action, facilitating penetration of activated immune cells, enhances activity immune checkpoint inhibition.
- **Take Home Message:** VX15/2503 was well-tolerated with a favorable safety profile in Phase I clinical trial; Phase1/2b combination trials with immune checkpoint inhibitors will be initiated in 2017.